The Most Promising New Cholesterol Drug Didn’t Work. Now What?
Novartis' pelacarsen, a cholesterol drug targeting lipoprotein(a), failed to reduce cardiovascular events in a clinical trial. The result questions whether lipoprotein(a) is a cause or marker of risk. Full data is pending, and other similar drugs are in trials. The company had high hopes for the drug, which had shown significant reductions in lipoprotein(a) levels.
How this was made
The 30-second read
Why it matters
The failure challenges the hypothesis that Lp(a) reduction translates to fewer events, affecting pipeline valuations.
Market read
First disclosure of a major cholesterol drug failure; may influence biotech valuations and investor sentiment.
What to watch
Trial participants were on aggressive LDL therapy; earlier intervention might yield different outcomes.
Background
Lipoprotein(a) is a genetic risk factor for heart disease; pelacarsen was a leading candidate to lower it.
Ticker impact
Novartis announced its pelacarsen trial failed to reduce cardiovascular events.
Potential short-term decline as investors reassess Lp(a) program.
First report of a pivotal Phase 3 failure for a major cholesterol drug.
Market effects
May dampen enthusiasm for Lp(a)-lowering therapies across biotech sector.
European pharma stocks could see modest pressure.
Limited to cholesterol drug pipeline investors worldwide.
Counterpoint
Longer-term data may still show benefit in subgroups; stock could rebound on future updates.
Key entities
- CompanyNovartis
Swiss pharma giant developing pelacarsen.
